The week of July 13, 2026, US Defense Secretary Pete Hegseth ordered annual testosterone-deficiency screening for active-duty and reserve service members aged 30 and older, framing it as a move to bolster military "readiness and performance." Within days, the directive drew sharp pushback: five of six men's-health experts contacted by Reuters said they were puzzled by the announcement and worried it could lead to unnecessary — or even harmful — treatment, according to coverage carried by Reuters, The Straits Times, Newsweek and Firstpost.

Why It Matters

The military is one of the largest single healthcare systems in the US, and a blanket testosterone-screening mandate for its 30-plus population could shift cultural and clinical norms far beyond the barracks — feeding directly into the booming TRT telehealth market. But the near-unanimous expert skepticism underscores the industry's core tension: destigmatized access to men's hormone therapy versus evidence-based prescribing. How the Pentagon handles "abnormal" results will be a real-world stress test of where that line sits.

The clinical objection is that routine population-wide testosterone screening of otherwise healthy men isn't supported by major urology or endocrinology guidelines, which reserve testing for men with actual symptoms of hypogonadism. Physicians warned that flagging "low" numbers in asymptomatic troops could push service members toward testosterone replacement therapy (TRT) they don't need — raising risks including infertility, and inviting inappropriate anabolic use. The Pentagon has not published detailed guidance on how abnormal results will be evaluated, or whether screening will apply equally to men and women. Hegseth said testing would come with advice to help members make treatment decisions, and that any treatment would be voluntary.

The order fits a pattern of contested health-policy moves from the current administration's defense and health leadership — the same reporting noted Hegseth's earlier reversal of the military flu-vaccine mandate (walked back after an outbreak) and HHS's removal of 17 members from a vaccine advisory panel. Critics see the testosterone mandate as part of a broader "masculinity and performance" framing of military fitness rather than an evidence-driven screening program.

For the sexual-health industry, the directive is a curious macro signal. It arrives as the FDA separately opens pathways toward approved testosterone indications for low libido and weighs descheduling testosterone, and as telehealth players (Hims, LifeMD's XYOSTED deal, Marius's Kyzatrex) race to expand TRT access. A government-mandated screening cohort of hundreds of thousands of men over 30 could normalize testosterone testing broadly — or, if it produces a wave of questionable prescriptions, become a cautionary tale about over-medicalizing "low-T."

Sources

Update — 2026-07-19

{Initial entry — story first created.}

Update — 2026-09-09

The guidance finally appeared — and vanished within 24 hours. On September 2, 2026, roughly seven weeks after Hegseth's July announcement, the Pentagon posted the clinical document implementing the policy: "Clinical Guidance for Health and Human Performance Optimization." By September 3 the memo and an accompanying statement from spokesperson Sean Parnell had both been pulled, with "Page Not Found" appearing on both the Pentagon and Defense Health Agency links. Reuters broke the withdrawal.

In a statement to Ars Technica, the Pentagon said the September 2 draft "has been temporarily rescinded to allow for updates," adding that interim guidance remains in effect and "the final clinical guidance will be issued shortly." The Department "remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members, and enabling peak operational performance." It declined to say what was being updated or why the revision was needed within a day of publication.

The now-withdrawn document filled in details the July announcement left blank, and they are directly relevant to this beat. Per Reuters via Military Times, it laid out separate screening paths for men and women during annual health assessments, effective immediately. Men 30 and older would be screened via questionnaire, which could trigger a blood test for testosterone and, if indicated, testosterone hormone therapy. Women would also be screened by questionnaire, potentially leading to treatment for hormonal imbalance conditions — with testosterone used in women only for diagnoses where there is evidence of efficacy, explicitly naming Hypoactive Sexual Desire Disorder, "characterized by a distressing level of low sexual interest." That is the first time this policy has been formally tied to a sexual health indication, and it puts the military in the position of screening service members for HSDD at scale.

Expert opposition has not softened since July. Ars Technica notes neither the Endocrine Society nor the American Urological Association supports routine low-testosterone screening. Dr. Jason Goldman, immediate past president of the American College of Physicians, told Reuters: "Taking testosterone is not going to make you more manly, more strong, or a more robust individual. That's just not how it works. It's just bad policy all around." Bradley Anawalt, chief of medicine at the University of Washington Medical Center, told Ars: "We're turning the clock back on rational health care. I'm worried about the ethics. I'm worried about the health consequences. I'm worried about unnecessary evaluations, incorrect assessments, and incorrect diagnoses that lead to inappropriate prescriptions of testosterone." Ars lists the risks of conventional TRT as decreased fertility, elevated red blood cell counts, acne, increased prostate size and sleep apnea, with higher doses associated with cardiovascular disease and prostate cancer.

For the TRT telehealth sector, the same-day retraction is a signal worth reading carefully. The prospect of a mandatory screening cohort numbering in the hundreds of thousands has been treated as a normalization tailwind for the category — but a policy that cannot survive 24 hours of public scrutiny is a shaky foundation to build a demand thesis on, and a clumsy rollout that produces a wave of questionable prescriptions would hand critics of direct-to-consumer testosterone exactly the case study they've been waiting for.

New Sources

Update — 2026-09-19

The guidance is back, it's final, and the women's version isn't in it. On Thursday September 17, 2026, the Department of Defense issued "Clinical Practice Guideline for Testosterone Deficiency in the Male Service Member," effective immediately per a Pentagon spokesperson — two months after Hegseth's July announcement and two weeks after the September 2 draft was published and rescinded within 24 hours. Health assessment questions across the military are being updated to match. The initiative sits inside the agency's Warfighter Performance Optimization program, which Hegseth announced in May.

The scope narrowed in the rewrite, and the narrowing is the story. Where the July memo indicated all service members would be tested, the final guidance applies only to men: every male service member aged 30 and above is directed to be screened at Periodic Health Assessments and on accession, with optional screening available for men under 30 (or, per Military Times, for those under 30 who show symptoms and request testing). Guidance for women is "still being reviewed," according to Vice Adm. Darin Via, director of the Defense Health Agency, and the Pentagon has not clarified whether women would be screened for estrogen or for testosterone therapy. That is a material change from the rescinded September 2 draft, which had a defined women's pathway including testosterone for Hypoactive Sexual Desire Disorder — the sexual-health indication Afterglow flagged in the September 9 update. It is now out of the operative document.

The sexual-health symptom list survived intact and remains the front door to the whole policy. Per the guidance's executive summary, screeners will look for "reduced libido, loss of spontaneous morning erections, erectile dysfunction, diminished energy and physical performance, impaired concentration, reduced muscle mass, and depressed mood," alongside risk factors including Type 2 diabetes, prior traumatic brain injury and sleep apnea. Positive screens route to laboratory testing. Treatment remains voluntary.

The most notable line in the document is the Defense Health Agency contradicting its own leadership. The guidance states that testosterone replacement therapy has a "demonstrated benefit for sexual function and improves body composition and bone mineral density" — and then adds: "Evidence does not support its use to improve energy, vitality, physical function, or cognition, and the American College of Physicians recommends against initiating therapy for those indications." Hegseth's July framing was explicitly about troops operating "at your absolute best," "restoring and optimizing your natural capabilities" and "the biological foundation required to sustain the fight." DHA's own clinical guideline says the evidence does not support that rationale. The guidance also notes low-testosterone symptoms "overlap substantially with the effects of sleep restriction, caloric deficit, psychological stress, mild traumatic brain injury, and mood disorders, all of which are prevalent in the operational population."

For the TRT telehealth sector, the final shape of this policy is narrower but more durable than the July version, and the positioning has flipped. The one indication the Pentagon's own clinicians will defend on evidence is sexual function — not performance, not vitality, not readiness. Operators marketing testosterone on energy and optimisation claims now have a federal clinical guideline on the record saying the evidence isn't there, while the sexual-health indication they have historically been most cautious about advertising is the one that holds up.

New Sources

Update — 2026-09-23

The operational fine print landed, and it has a career-consequences clause. Federal News Network reported September 18, 2026 on the Defense Health Agency's rollout of the actual clinical guidelines providers will use, filling in the mechanics the September 17 announcement left abstract. The screen is a questionnaire first, not a blood draw: providers ask male troops over 30 — and new recruits of any age on accession — about symptoms and risk factors, and only escalate to blood tests, diagnosis and possible hormone therapy if the answers raise flags. Risk factors named include obesity, diabetes, prior traumatic brain injury or bone injury, and sleep apnea. Men under 30 can request a screening.

The consequential detail is deployment and duty status. DHA's guidance states that "a service member who is stable on testosterone therapy should be deployable without requiring a waiver, depending on the formulation," and that "neither a diagnosis of testosterone deficiency nor stable maintenance therapy is, of itself, a basis for a duty limitation or a change in deployment status." But the guidance warns that troops in aeromedical, dive, submarine and nuclear fields may be disqualified for duty if diagnosed with testosterone deficiency, with service officials making the final call. Deploying on TRT also carries a supply-chain requirement — treatment must last the deployment plus 90 days, which gets complicated if a tour extends, if there is no temperature-controlled storage for injectables, or if topicals are not permitted at the destination.

Fertility got an explicit carve-out that the sexual-health sector should note: DHA says men who may want children can choose treatments that raise testosterone without suppressing sperm production, or pursue cryopreservation. That is the first time a federal clinical guideline of this scale has routed a testosterone population toward fertility preservation as standard counseling — a meaningful signal for Legacy, Bird&Be and the rest of the male-fertility segment.

Pentagon spokesman Sean Parnell framed the program as investing "in the health of its warfighters," and Hegseth said the initiative "is not about artificial enhancement; it's about restoring and optimizing your natural capabilities." Federal News Network notes the unresolved tension critics keep raising: the department is encouraging hormone therapy for some service members while deeming hormone treatment for transgender troops incompatible with military service. On the women's side, defense officials are still reviewing companion guidance that Federal News Network reports "could formalize a path to relief for women looking to manage the symptoms of perimenopause and menopause." No release date has been given.

New Sources

Update — 2026-10-05

The fertility guardrail in the guideline. A September 30, 2026 Military.com analysis of the Defense Health Agency's Clinical Practice Guideline for Testosterone Deficiency in the Male Service Member (dated September 17) points to a clause most coverage missed. Providers must "ask about fertility intent before any prescription." If a service member wants children or hasn't decided, the guideline says "exogenous testosterone will not be initiated." Providers are instead directed to hCG (human chorionic gonadotropin, FDA-approved for hypogonadotropic hypogonadism in males) or, off-label, clomiphene citrate, both of which raise testosterone without shutting down sperm production. Only men who don't want children, or have finished having them, go to standard TRT. The guideline does not test every service member's blood. It starts with a symptom and risk-factor screen, and only those who screen positive get two separate early-morning blood draws on different days.

Per NewsBlaze, the Endocrine Society responded on September 24 that evidence does not support population-level screening in asymptomatic men, citing the risk of false positives and fertility harm. Its objection is unchanged, but the policy is now in effect.

Why it matters: This is the strongest fertility-first prescribing rule we have seen from any large US health system, and it goes further than much consumer TRT telehealth practice. For the men's-health market, the military, a large payer that sets norms, is now effectively labeling hCG/clomiphene-first protocols as the standard of care for men of reproductive age. Platforms selling TRT to men in their 20s and 30s, and the sperm-testing companies that benefit from fertility-intent conversations (Legacy, at-home semen-analysis kits), should take note.

New Sources

Update — 2026-10-17

The first hard numbers: about one in four. On October 15, 2026, JAMA published a study by researchers at Pennington Biomedical Research Center and the U.S. Army Research Institute of Environmental Medicine. It estimates how many soldiers the Pentagon's new screening will flag. Using the Military Health and Nutrition Examination Study, which tested 479 male active-duty soldiers at five military centres between 2024 and 2026, 26% had morning testosterone below the American Urological Association's 300 ng/dL threshold. That was 20% among men under 30 and 32.8% among those 30 and older, the group now screened every year (Military Times; New Scientist). Extrapolated to the force, the authors estimate 100,691 active-duty soldiers would fall below the cutoff. They concluded that routine screening "will result in confirmatory testing and clinical evaluation for many male service members." Military Times notes the rates are similar to those in the general US male population.

Outside experts focused on what happens next. Darren Katz of the University of Melbourne, who was not involved in the study, told New Scientist that a single measurement is unreliable because levels move with time of day, food, sleep, obesity, illness and stress. He added that "there is currently insufficient evidence that [therapy] will improve military readiness, operational performance or fighting capacity." On October 16, MS NOW reported a new detail from the Defense Health Agency guidance. Troops who stay on therapy while deployed must show testosterone in a 300–600 ng/dL target range at a follow-up four to six weeks later. The outlet also recalled chief Pentagon spokesman Sean Parnell's mid-September post: "We are building a High-T department focused on strength, performance, lethality." The Pentagon still hasn't said whether refusing recommended treatment has consequences, and screening guidance for women remains pending with no date.

What changed: The policy now has a number attached. If about a third of men aged 30 and older screen low on a first test, the military health system faces a large wave of confirmatory testing. Even if only some of those men start therapy, the military becomes one of the largest institutional TRT prescribers in the country, with a fertility-intent rule (see the Oct 5 update) that consumer telehealth doesn't apply. The two-morning-test rule and the 300–600 target range give men's-health telehealth a public benchmark it will be measured against.

New Sources

Update — 2026-10-25

HHS turns the screening into a national-security talking point. In an interview with Fox News Digital published October 24, 2026 (syndicated by the New York Post), Adm. Brian Christine, a senior HHS official and a urologist of 35+ years who helped shape the initiative behind the Pentagon's September screening guideline, said "there is absolutely national defense readiness ramifications" for low testosterone. He tied the policy to recruiting, citing 77% of Americans aged 17–24 who can't qualify for service without a waiver. He also claimed average U.S. male testosterone has fallen from "well over 650" in the mid-1970s to "approaching 350." That is his figure, and neither outlet sourced it. He also said, "We're not forcing testosterone on anybody… we are screening, taking those men who are symptomatic and have low numbers and offering them a pathway forward." NIH Director Jay Bhattacharya told the same outlet "there are under-diagnosed testosterone deficiencies" and said NIH is funding research into causes, including possible environmental factors behind falling sperm counts.

The same weekend, a ScienceAlert write-up (October 24) brought back a Journal of the Endocrine Society review from the University of Kansas Medical Center and Kansas City VA (Maligireddy, Barua et al.; Endocrine Society release September 1). It found that both low and high testosterone are associated with atrial fibrillation and that risk may be lowest in the middle of the normal range. It cites the TRAVERSE trial's AF signal (3.5% on testosterone gel vs 2.4% on placebo) and the authors recommend cardiac assessment before treatment. The review is observational and has not been shown to change outcomes, but it argues against "more is better" dosing.

What changed: The policy now has federal health leadership, not just DoD, publicly backing it with a population-decline argument. That gives it a wider audience than the military, and men's-health telehealth marketing will likely pick up the same message. The AF review is the clinical counterweight. It supports the DHA guideline's 300–600 ng/dL target band (see the October 17 update) and cuts against high-normal "optimization" protocols. Platforms like Hims now face a policy narrative that encourages screening alongside evidence that argues for conservative dosing targets.

New Sources